Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Retained Earnings (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Retained Earnings data on record, last reported at -$1.5 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 23.37% year-over-year to -$1.5 billion; the TTM value through Dec 2025 reached -$1.5 billion, down 23.37%, while the annual FY2025 figure was -$1.5 billion, 23.37% down from the prior year.
  • Retained Earnings reached -$1.5 billion in Q4 2025 per SNDX's latest filing, down from -$1.4 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$543.7 million in Q4 2021 and bottomed at -$1.5 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$909.3 million, with a median of -$804.4 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: increased 4.38% in 2021, then plummeted 35.79% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$543.7 million in 2021, then fell by 27.47% to -$693.0 million in 2022, then plummeted by 30.21% to -$902.4 million in 2023, then crashed by 35.32% to -$1.2 billion in 2024, then fell by 23.37% to -$1.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.5 billion in Q4 2025, -$1.4 billion in Q3 2025, and -$1.4 billion in Q2 2025.